Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients

Neurobiology of Disease

Volumn 15, Issue 2, 2004, Pages 351-360

  Hellstrom Lindahl E ^a   Mousavi, M ^a   Ravid, R ^b   Nordberg, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

Alzheimer's disease; Amyloid peptide; Human brain; Nicotine; Nicotinic receptors; Smoking

Indexed keywords

ALPHA BUNGAROTOXIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CYTISINE; EPIBATIDINE; IODINE 125; NICOTINE; NICOTINIC RECEPTOR; TRITIUM; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BUNGAROTOXIN; CYSTINE; FUSED HETEROCYCLIC RINGS; NICOTINIC AGENT; PEPTIDE FRAGMENT; PYRIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; PATIENT; PRIORITY JOURNAL; RECEPTOR BINDING; SMOKING; SOLUBILITY; TEMPORAL CORTEX; UPREGULATION; DOWN REGULATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RADIOASSAY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; BRAIN; BUNGAROTOXINS; CYSTINE; DOWN-REGULATION; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PEPTIDE FRAGMENTS; PYRIDINES; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; SMOKING; TRITIUM;

EID: 1542270719     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.11.024     Document Type: Article

References (75)

1. Almeida O.P., Hulse G.K., Lavrence D., Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systemic review of case-control and cohort studies. Addiction. 97:2002;15-28.
2. Arriagada P.V., Growdon J.H., Hedley W.E., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
3. swe transgenic mice. Mol. Cell Neurosci. 20:2002;354-365.
4. Bednar I., Hellström-Lindahl E., Mousavi M., Nordberg A., Lee M., Johnson M., Hal R., Perry E., Court J. Nicotine treatment attenuates beta-amyloidosis in brain of transgenic APP swe mice. Neurobiol. Aging. 23(1S):2002;1012.
5. Benwell M.E., Balfour D.J., Anderson J.M. Evidence that tobacco smoking increases the density of (-)-[3H] nicotine binding sites in human brain. J. Neurochem. 50:1988;1243-1247.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer's-related changes. Acta Neuropathol. 82:1991;239-259.
7. Braak H., Braak E. Evolution of neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165:1996;3-12.
8. Breese C.R., Marks M.J., Logel J., Adams C.E., Sullivan B., Collins A.C., Leonard S. Effect of smoking history on [3H] nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:1997;7-13.
9. Burghaus L., Schutz U., Krempel U., de Vos R., Jansen Steur E.N., Wevers A., Lindstrom J., Schroder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Mol. Brain Res. 76:2000;385-388.
10. Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N., Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6826-6831.
11. Court J.A., Lloyd S., Thomas N., Piggott M.A., Marshall E.F., Morris C.M., Lamb H., Perry R.H., Johnson M., Perry E.K. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience. 87:1998;63-78.
12. Dani J.A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry. 49:2001;166-174.
13. Dineley K.T., Westerman M., Bui D., Bell K., Ashe K.H., Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 21:2001;4125-4133.
14. Evin G., Weidemann A. Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides. 23:2002;1285-1297.
15. French S.J., Humby T., Horner C.H., Sofroniew M.V., Rattray M., Flores C.M., Rogers S.W., Pabreza L., Wolf B., Kellar K.J. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol. Brain Res. 6:1999;124-136.
16. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. β-secretase protein and activity are increased in the neocortex in Alzheimer's disease. Arch. Neurol. 59:2002;1381-1389.
17. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R., Ihara Y. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152:1998;1633-1640.
18. 1-42 peptide alters the gating of human and mouse β-bungarotoxin-sensitive nicotinic receptors. J. Physiol. 547:2003;147-157.
19. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 74:2000;237-243.
20. Hellström-Lindahl E., Gorbounova O., Seiger Å., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Dev. Brain Res. 108:1998;147-160.
21. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Mol. Brain Res. 66:1999;94-103.
22. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D., Hoffmann J.F., Maddalena M., Papassotiropoulos A., Nitsch R.M. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554.
23. Holsinger R.M., Mc Lean C.A., Beyreuther K., Masters C.L., Evin G. Increase expression of amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. 51:2002;783-786.
24. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St. George-Hyslop P.H., Mirra S.S., Mori H. Aβ 1-40 but not Aβ 1-42 levels in cortex correlate with apolipoprotein E (4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748:1997;250-252.
25. 1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6:2000;143-150.
26. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Christhi M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St. George-Hyslop P., Westaway D. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
27. Kaiser S., Soliakov L., Wonnacott S. Presynaptic neuronal nicotinic receptors: pharmacology, heterogeneity, and cellular mechanisms. Clementi F., Fornasari D., Gotti C. Neuronal nicotinic receptors. Experimental Pharmacology. vol. 14:2000;193-211 Springer, Berlin.
28. Kim S.H., Kim Y.K., Jeong S.J., Haass C., Kim Y.H., Suh Y.H. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol. Pharmacol. 52:1997;430-436.
29. Kukull W.A. The association between smoking and Alzheimer's disease: effects of study design and bias. Biol. Psychiatry. 49:2001;194-199.
30. Kuo Y.-M., Emmerling M.R., Bisgaier C.L., Essenburg A.D., Lampert H.C., Drumm D., Roher A.R. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem. Biophys. Res. Commun. 252:1998;711-715.
31. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 13:1994;131-144.
32. Levin E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53:2002;633-640.
33. Li M.D., Kane J.K., Matta S.G., Blaner W.S., Sharp B.M. Nicotine enhance the biosynthesis and secretion of transthyretin from the choroids plexus in rats: implications for β-amyloid formation. J. Neurosci. 20:2000;1318-1323.
34. Liu Q., Kawai H., Berg D. Beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4734-4739.
35. Lloyd G.K., Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 292:2000;461-467.
36. Lue L.-F., Kuo Y.-M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862.
37. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 73:1999;1635-1640.
38. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866.
39. Mc Khann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task forces on Alzheimer's disease. Neurology. 34:1984;939-944.
40. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hacher J., Hope C., Gordon M., Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
41. Mousavi M., Hellstrom-Lindahl E., Guan Z.-Z., Shan K.-R., Ravid R., Nordberg A. Protein and mRNA level of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Neuroscience. 122:2003;515-520.
42. Mukherjee A., Hersh L.B. Regulation of amyloid β-peptide levels by enzymatic degradation. J. Alzheimer's Dis. 4:2002;341-348.
43. 1-42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 110:2002;199-211.
44. Näslund J., Haroutunian V., Mohs R., Davies K.L., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid β-peptide in brain and cognitive decline. JAMA. 283:2000;1571-1577.
45. Newhouse P.A., Potter A., Kelton M., Corwin J. Nicotine treatment of Alzheimer's disease. Biol. Psychiatry. 49:2001;268-278.
46. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9:2003;448-452.
47. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4:1992;303-328.
48. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatry. 49:2001;200-210.
49. Nordberg A., Hellström-Lindahl E., Lee M., Johnson M., Mousavi M., Hall R., Perry E., Bednar I., Court J. Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J. Neurochem. 81:2002;655-658.
50. Parvathy S., Davies P., Haroutunian V., Purohit D.P., Davis K.L., Mohs R.C., Park H., Moran T.M., Chan J.Y., Buxbaum J.D. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch. Neurol. 58:2001;2025-2032.
51. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61:2000;75-111.
52. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1999;1545-1552.
53. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Näslund J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 393:2000;215-225.
54. Pettit D., Shao Z., Yakel J. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21(RC120):2001.
55. Picciotto M.R., Zoli M. Nicotinic receptors in aging and dementia. J. Neurobiol. 53:2001;641-655.
56. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45:1999;358-368.
57. Ravid R., Swaab D.F., Kamphorst W., Salehi A. Brain banking in aging and dementia research - The Amsterdam experience. Fisher A., Yorshida M., Hanin I. Progress in Alzheimer's and Parkinson's Disease. 1998;277-286 Plenum, New York.
58. Reisberg B., Ferris S.H., Del Leon M.J., Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychol. 139:1982;1136-1139.
59. Rossner S., Ueberham U., Schliebs R., Perez-Polo J.R., Bigl V. Regulated secretion of amyloid precursor protein by TrkA receptor stimulation in rat pheochromocytoma-12 cells is mitogen activated protein kinase sensitive. Neurosci. Lett. 271:1999;97-100.
60. Salomon A.R., Marcinowski K.J., Friedland R.P., Zagorski M.G. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry. 35:1996;13568-13578.
61. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
62. Schwarzman A.L., Gregori L., Vitek M.P., Lyubski S., Strittmatter W.J., Enghilde J.J., Bhasin R., Silverman J., Weisgraber K.H., Coyle P.K. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8368-8372.
63. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43:2003;545-584.
64. Shimohama S., Kihara T. Nicotinic receptor-mediated protection against β-amyloid neurotoxicity. Biol. Psychiatry. 49:2001;233-239.
65. Svensson A.-L., Nordberg A. β-Estradiol attenuate amyloid β-peptide toxicity via nicotinic receptors. NeuroReport. 10:1999;3485-3489.
66. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physiological bases of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
67. Thal D.R., Rüb U., Orantes M., Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 58:2002;1791-1800.
68. Tyler S.J., Dawbarn D., Wilcock G.K., Allen S.J. β- and β-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. 299:2002;373-376.
69. Utsuki T., Shoaib M., Holloway H.W., Ingram D.K., Wallace W.C., Haroutunian V., Sambamurti K., Lahiri D.K., Greig N.H. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid-beta-peptide in rat. J. Alzheimer's Dis. 4:2002;405-415.
70. van Duijn C.M., Clayton D.G., Chandra V., Fratiglioni L., Graves A.B., Heyman A. Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. Genet. Epidemiol. 1:1994;539-551.
71. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20:2000;1657-1665.
72. Wang J., Dickson D.W., Trojanowski J.Q., Lee V.M.-Y. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 58:1999;328-337.
73. Wang H.-Y., Lee D.H.S., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. β-amyloid 1-42 binds α7 nicotinic acetylcholine receptor with high affinity. J. Biol. Chem. 275:2000;5626-5632.
74. Zamani M.R., Allen Y.S. Nicotine and its interaction with β-amyloid protein: a short review. Biol. Psychiatry. 49:2001;221-232.
75. Zeng H., Zhang Y., Peng L.-J., Shao H., Menon N.K., Yang J., Salomon A.R., Freidland R.P., Zagorski M.G. Nicotine and amyloid formation. Biol. Psychiatry. 49:2001;248-257.